Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Priority Prescription Cards Help Japan Promote Generics?

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Struggling to promote the use of generic drugs, now stalled around 17 percent of total Japanese prescription drug sales, Japan's Ministry of Health, Labor and Welfare will distribute "generic prescription priority cards" to all National Health Insurance policyholders as part of its fiscal 2009 budget, MHLW officials told PharmAsia News Jan. 13

You may also be interested in...



Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch

Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast

Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch

Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast

Eisai Sees Generics Opportunity In Japan For Innovator Companies

A push by the Japanese government to increase generic drug utilization is an opportunity for innovator companies to jump into the generics space following Japanese patent expiries, according to Eisai CEO Haruo Naito

Related Content

UsernamePublicRestriction

Register

SC069810

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel